Rarity Bioscience

Executive Summary

Rarity Bioscience is a Swedish molecular diagnostics company that has developed superRCA®, a proprietary ultra-sensitive assay technology for detecting rare nucleic acid sequences, such as cancer mutations, in liquid biopsy and tissue samples. Founded in 2021 as a spin-out from Uppsala University, the company addresses a critical need in precision medicine: enabling reliable early detection and monitoring of cancer from minimally invasive blood draws. The superRCA® platform offers single-molecule sensitivity, which could significantly improve the ability to detect residual disease and guide treatment decisions. While still in early commercialization stages, Rarity Bioscience has the potential to become a key player in the rapidly growing liquid biopsy market, projected to exceed $20 billion by 2030. The company's success will depend on securing clinical validation, forming strategic partnerships with diagnostic or pharmaceutical firms, and scaling manufacturing. Its technology represents a promising advance over current methods, such as digital PCR and NGS, particularly for mutation detection in samples with low tumor fraction.

Upcoming Catalysts (preview)

• Q3 2026First Clinical Validation Study Results70% success
• Q4 2026Partnership with Major Pharma for Companion Diagnostic Development40% success
• Q2 2026Series A Funding Round Completion80% success